Refine Search

New Search

Result: 1

(searched for: doi:10.3389/fonc.2019.00365)
Save to Scifeed
Page of 1
Articles per Page
by
Show export options
  Select all
I. V. Menshikova, V. V. Strogonova
Published: 4 September 2020
Rheumatology Science and Practice, Volume 58; https://doi.org/10.47360/1995-4484-2020-443-446

Abstract:
Immunotherapy with immune checkpoint inhibitors (ICIs) opens up new prospects in treatment of malignancies, although this novel therapy quite often results in development of immune-related adverse events (irAEs), which can limit their clinical use. IrAEs can affect almost any organ system, including the endocrine, respiratory, digestive, nervous, other organs and the skin. Most often irAEs are characterized by moderate degree of severity, but complications are fatal in 2% of patients.The nature of irAEs significantly differs from the adverse reactions associated with use of standard chemotherapeutic agents, which usually cause immunosuppression (due to neutropenia). Of particular interest to clinicians are rheumatic irAEs, which can occur at any time after treatment and tend to persist even after ICIs discontinuation. This review analyzes the prevalence, clinical characteristics, and approaches to treatment of rheumatic irAEs.
Page of 1
Articles per Page
by
Show export options
  Select all
Back to Top Top